Please login to the form below

Not currently logged in
Email:
Password:

Roche wins FDA priority review for haemophilia A drug

Emicizumab prophylaxis could be approved early next year

Roche

The US Food and Drug Administration (FDA) has awarded priority review status to Roche’s emicizumab prophylaxis, a once weekly subcutaneous treatment used in conjunction with factor VIII inhibitors for patients with haemophilia A.

The decision follows the phase III HAVEN 1 study in adults and adolescents, as well as interim results from the phase III HAVEN 2 study in children younger than 12 years of age.

Sandra Horning, Roche’s chief medical officer, said: “Results of our phase III study in adults and adolescents as well as early phase III results in children showed that emicizumab has significant potential to help people with haemophilia A with inhibitors, who face major challenges in preventing and treating bleeds.”

Haemophilia affects around 320,000 people worldwide, with 50-60% of that number suffering from a ‘severe’ form of the disorder.

Horning added: “We are working with the FDA to hopefully bring this new prophylactic treatment option to the haemophilia A inhibitor community as soon as possible.”

The FDA is expected to make a decision on the pharma giant’s injection late February next year.

Meanwhile, Roche has additional trials of the drug ongoing, with and without inhibitors, to explore other, less frequent dosing regimens.

Article by
Gemma Jones

29th August 2017

From: Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
JPA Health

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

Cervical Cancer Prevention Month
In this first 2022 blog, the Innovative Trials' Equality & Diversity committee will be looking at raising awareness around Cervical Cancer...
6 critical success factors for flawless execution of a rapid first commercial launch
Annemarie Armstrong, Executive Vice President, US Head of Client Services, shares the key considerations for launching a first commercial product, particularly on a rapid timeline....
Hybrid working: Insights and tips for success
Porterhouse Medical has thrived by embracing a hybrid approach to work. Our article looks at hybrid working and provides some tips for success...